luminespib previously known experimental drug candidate treatment cancer discovered collaboration institute cancer research pharmaceutical company licensed phase ii clinical chemically resorcinylic isoxazole luminespib inhibitor heat shock protein chaperone protein plays role modification variety proteins implicated oncogenesis luminespib shown promising activity preclinical testing several different tumor related compound abandoned novartis failed show efficacy early clinical antineoplastic immunomodulatory drug article stub help wikipedia expanding httpsenwikipediaorgwikiluminespib